Episode

Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

Podcast: Decera Clinical Education Oncology Podcast
Published: May 7, 2026
Duration seconds: 1860
Processing state: not_requested
Canonical source: https://oncologypodcast.simplecast.com/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma-g4ris29j
Audio: https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/e008a55d-649a-4523-bbb3-d6a1070944e5/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=e008a55d-649a-4523-bbb3-d6a1070944e5&feed=GlfUTtJq
JSON: /v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma
Markdown: /podcast/decera-clinical-education-oncology-podcast-1302999/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma.md

Actions

POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Enhance your knowledge and optimize treatment for patients with R/R MM by learning from subject matter experts Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, in this podcast. Listen as they discuss various strategies to optimize the use of bispecific antibodies in their practices through patient monitoring, dosing in outpatient settings, and utilizing tocilizumab and IVIG among other management strategies.